PCR81 Evaluating Patient Preferences for Clinical Trial Endpoints in Early Stage Cancer: A Discrete Choice Experiment in Canada
2025 · Value in Health · 0 citations
https://doi.org/10.1016/j.jval.2025.09.2554
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
80
Citations
2
h-index
2
i10-index
Kristoph Klein-Panneton is an academic researcher from AstraZeneca (Canada). The author has contributed to research in topics: Neurogenetic and Muscular Disorders Research & HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies. The author has an h-index of 2, co-authored 9 publications.
Click to start Chat